Electrical Vestibular Stimulation (VeNS), Compared to a Sham Control For The Management Of Anxiety

Anxiety Clinical Trial

Official title:

A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate The Efficacy of Electrical Vestibular Stimulation (VeNS), Compared to a Sham Control For The Management Of Anxiety

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05907967
• Other study ID #: UUS002
• Status: Completed
• Phase: N/A
• Start date: July 18, 2022
• Est. completion date: April 20, 2023

Study information

• Verified date: January 2024
• Source: Neurovalens Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Anxiety is known to be one of the most common health concerns in in the general population, and the most common mental health issue, and has been associated with several health consequences. Medications are known to be effective, and currently serve as the primary treatment for anxiety but comes with a risk of adverse effects. Cognitive Behavioral Therapy (CBT-1) has also been shown to be effective and safer in the treatment of anxiety but presents its own limitations such as the time, cost, and training required. The relationship between vestibular stimulation and anxiety continues to be explored, however its usefulness in the treatment of anxiety is still unknown. Vestibular stimulation itself has been shown to be safe across multiple populations. If vestibular stimulation is shown to be effective in the treatment of anxiety, it could serve as a safer alternative to medications. It could also require less cost, time, and training than CBT-1, providing a treatment option that is not only safe and effective, but broadly available to the general population. It also could present an alternative intervention for patients who are non-responsive or refuse medication. Consequently this trial seeks to evaluate the efficacy of non-invasive electrical vestibular nerve stimulation as a method of improving sleep quality and quantity, as compared to a sham control, in patients newly diagnosed with anxiety.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 83
• Est. completion date: April 20, 2023
• Est. primary completion date: April 20, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Signed informed consent

• Male or female, age = 18 years and = 80 years at the time of signing informed consent.

• Report clinically significant symptoms of anxiety, defined as a score of 10 or greater on the Generalized Anxiety Disorder Scale, 7th edition (GAD-7)

• Ability and willingness to complete all study visits and procedures

• Agreement to engage with using the device on a daily basis

• Agreement to engage with trial mentors

• Agreement not to use prescription, or over the counter, anxiety medications for the duration of the trial

• Access to Wi-Fi

• Access to Apple smart phone (If not an Apple iPod will be supplied)

Exclusion Criteria:

• History of skin breakdown, eczema or other dermatological condition (e.g. psoriasis) affecting the skin behind the ears.

• Previous diagnosis of HIV infection or AIDS (HIV is known to cause a vestibular neuropathy which would prevent VeNS from working)

• Use of beta-blockers within 1 month of starting the study

• Use of antidepressants or unstable dose within 3 months of starting study

• Medication for anxiety (unless regime stable for last 3 months).

• A history of stroke or severe head injury (as defined by a head injury that required a craniotomy or endotracheal intubation). (In case this damaged the neurological pathways involved in vestibular stimulation).

• Presence of permanently implanted battery powered medical device or stimulator (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator etc.).

• Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice)

• History of epilepsy

• History of active migraines with aura

• History of head injury requiring intensive care or neurosurgery

• History of cognitive impairment

• History of of bipolar, psychotic or substance use disorders

• Regular use (more than twice a month) of antihistamine medication within the last 6 months.

• History or presence of malignancy within the last year (except basal and squamous cell skin cancer and in-situ carcinomas)

• A diagnosis of myelofibrosis or a myelodysplastic syndrome.

• Previous use of Modius device

• Participation in other clinical trials sponsored by Neurovalens

• Participation in any other anxiety studies

• Have a member of the same household who is currently participating in this study.

• Not fluent in English language

• History of vestibular dysfunction or other inner ear disease

Related Conditions & MeSH terms

• Anxiety
• Anxiety Disorders

Intervention

Device:
• VeNS
The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.

Locations

Country	Name	City	State
United Kingdom	Ulster University	Coleraine

Sponsors (2)

Lead Sponsor	Collaborator
Neurovalens Ltd.	Ulster University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Generalised Anxiety Disorder (GAD-7) Scores	To evaluate the effect of the VeNS device, relative to control group on participants with anxiety (range 0-21) with higher score indicating more severe anxiety.	4 weeks
Secondary	Number of adverse events	To evaluate the safety of the VeNS device relative to control group, in terms of the occurrence of adverse events.	4 weeks
Secondary	Quality of life using SF-36 scores	To evaluate the effect of the VeNS device, relative to control group, on quality of life. SF-36 is a 36-item short form survey (range 0-100) with higher scores indicating a better quality of life.	4 weeks
Secondary	Insomnia Severity Index (ISI) score	To evaluate the effect of the VeNS device, relative to control group on participants with insomnia. ISI is a self-report rating scale assessing the severity of insomnia symptoms (range 0-28) with higher scores indicating a more severe insomnia.	4 weeks